A Randomized Trial (Irish Clinical Oncology Research Group 97-01) Comparing Short Versus Protracted Neoadjuvant Hormonal Therapy Before Radiotherapy for Localized Prostate Cancer

Armstrong, John G.; Gillham, Charles; Dunne, Mary; Fitzpatrick, David; Finn, Marie; Cannon, Mairín E.; Taylor, Judy C; O'Shea, Carmel; Buckney, Steven J.; Thirion, P.

doi:10.1016/j.ijrobp.2010.04.065

Cited by 43 publications

(34 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). 31,34,35 A similar observation was recently made by Tseng et al 36 D'Amico et al performed a systematic review of 2 RCTs using Prentice criteria to assess whether PSA nadir or PSA end concentrations > 0.5 ng/mL were surrogates for PCaspecific mortality. 36,37 In both trials, men receiving RT and 6 months of ADT were significantly less likely to have PSA end and PSA nadir values > 0.5 ng/mL versus those treated with RT alone (P < .0001).…”

Section: Long-term Adjuvant Adt Plus Rt Versus Adt Alonementioning

confidence: 59%

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

Roach

2014

Cancer

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is now a well‐established standard of care in combination with definitive radiotherapy for patients with unfavorable intermediate‐risk to high‐risk locally advanced prostate cancer. It is also well established that combination modality treatment with ADT and radiotherapy is superior to either of these modalities alone for the treatment of patients with high‐risk locally advanced disease. Current treatment guidelines for prostate cancer in the United States are based on the estimated risk of recurrence and death. This review examines the clinical evidence underpinning the use of ADT and radiotherapy among patients with high‐risk localized and locally advanced disease in the United States. This review also considers the rationale for moving from traditional luteinizing hormone‐releasing hormone agonists to more recently developed gonadotrophin‐releasing hormone antagonists. Cancer 2014;120:1620–1629. © 2014 American Cancer Society.

show abstract

Section: Long-term Adjuvant Adt Plus Rt Versus Adt Alonementioning

confidence: 59%

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

Roach

2014

Cancer

View full text Add to dashboard Cite

show abstract

“…The Irish Clinical Oncology Research Group 97-01 study was conducted from 1997 to 2001 [18]. This study randomized 261 patients with localized, node negative, intermediate to high risk, PSA > 20 disease to 70 Gy of radiation with either a short (4 month) or long (8 month) course of neoadjuvant hormone therapy (LHRH with flutamide).…”

Section: Discussionmentioning

confidence: 99%

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation

Ludwig

Kuban

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

BackgroundTo determine whether the effect of androgen deprivation therapy (ADT) on the risk of biochemical failure varies at different doses of radiation in patients treated with definitive external beam radiation for intermediate risk prostate cancer (IRPC).MethodsThis study included 1218 IRPC patients treated with definitive external beam radiation therapy to the prostate and seminal vesicles from June 1987 to January 2009 at our institution. Patient, treatment, and tumor information was collected, including age, race, Gleason score, radiation dose, PSA, T-stage, and months on ADT.ResultsThe median follow-up was 6 years. A total of 421(34.6%) patients received ADT, 211 (17.3%) patients experienced a biochemical failure, and 38 (3.1%) developed distant metastasis. On univariable analyses, higher PSA, earlier year of diagnosis, higher T-stage, lower doses of radiation, and the lack of ADT were associated with an increased risk of biochemical failure. No difference in biochemical failure was seen among different racial groups or with the use of greater than 6 months of ADT compared with less than 6 months. On multivariate analysis, the use of ADT was associated with a lower risk of biochemical failure than no ADT (HR, 0.599; 95% CI, 0.367-0.978; P < 0.04) and lower risk of distant metastasis (HR, 0.114; 95% CI, 0.014-0.905; P = 0.04).ConclusionsADT reduced the risk of biochemical failure and distant metastasis in both low- and high dose radiation groups among men with intermediate-risk PCa. Increasing the duration of ADT beyond 6 months did not reduce the risk of biochemical failures. Better understanding the benefit of ADT in the era of dose escalation will require a randomized clinical trial.

show abstract

“…A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before RT for localized prostate cancer was designed to examine the long-term outcomes of a randomized trial comparing short (4 months) and long (8 months) neoadjuvant hormonal therapy before RT for localized PCa [105] (Table 14). No statistically significant difference was found in biochemical failure-free survival between 4 months and 8 months of neoadjuvant hormonal therapy before RT for localized PCa.…”

Section: Optimal Timing and Duration Of Androten Deprivation Therapy mentioning

confidence: 99%

“…randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer[105].…”

mentioning

confidence: 99%

Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer

Nishiyama

2012

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

A Randomized Trial (Irish Clinical Oncology Research Group 97-01) Comparing Short Versus Protracted Neoadjuvant Hormonal Therapy Before Radiotherapy for Localized Prostate Cancer

Cited by 43 publications

References 41 publications

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation

Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer

Contact Info

Product

Resources

About